Pola-ZR2P in Previously Untreated DLBCL
The goal of this phase 2 trial is to test the safety and efficacy of Pola-ZR2P as induction therapy in patients with DLBCL.
Diffuse Large B-cell Lymphoma
DRUG: Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy
Overall Response Rate (ORR), ORR was defined as the proportion of patients who achieved CR or PR, 1 year
Overall Survival (OS), OS was defined as time from diagnosis to death from any cause or the last follow-up, through study completion, an average of 2 years|Progression Free Survival (PFS), Progression was defined according to the Lugano Response Criteria, 2 years
The investigators will evaluate safety and efficacy of Pola-ZR2P as induction therapy in Previously Untreated Diffuse Large B-Cell Lymphoma. ORR(Overall response rate, progression-free survival (PFS), overall survival (OS), adverse events (AEs) will be assessed.